|By PR Newswire||
|September 4, 2014 07:00 AM EDT|
SANTA ROSA, Calif., Sept. 4, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 2:30 p.m. ET. The conference will be held at the New York Palace Hotel in New York City.
A live webcast of Ruthigen's presentation may be available at the following website: http://wsw.com/webcast/rrshq24/rtgn. After the presentation, a replay will be archived and accessible for 90 days at the same website.
Ruthigen is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications. The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective containing a new formulation of hypochlorous acid, HOCl, with small molecule stabilizers that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures. RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs. The Company plans to complete its Phase I/II clinical trial in Q1 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials. The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery. The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B. For more information, visit www.ruthigen.com.
SOURCE Ruthigen, Inc.
"Dice has been around for the last 20 years. We have been helping tech professionals find new jobs and career opportunities," explained Manish Dixit, VP of Product and Engineering at Dice, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 01:45 PM EST Reads: 1,099
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Dec. 7, 2016 01:30 PM EST Reads: 342
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
Dec. 7, 2016 01:30 PM EST Reads: 2,142
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 01:24 PM EST Reads: 102
Dec. 7, 2016 12:45 PM EST Reads: 1,070
Dec. 7, 2016 12:35 PM EST Reads: 210
Dec. 7, 2016 12:30 PM EST Reads: 835
Dec. 7, 2016 12:30 PM EST Reads: 611
Dec. 7, 2016 12:30 PM EST Reads: 716
Dec. 7, 2016 12:00 PM EST Reads: 1,113
Dec. 7, 2016 12:00 PM EST Reads: 590
Dec. 7, 2016 11:47 AM EST Reads: 247
Dec. 7, 2016 11:45 AM EST Reads: 1,023
Dec. 7, 2016 11:45 AM EST Reads: 457
Dec. 7, 2016 11:30 AM EST Reads: 653